Tag: Auris Medical

All

Latest

Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement

On August 20, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed.

All

Latest

Auris Medical Holding AG Announces Launch and Pricing of IPO

Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company’s common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.

Read More
Loading